NCT06926283

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

A Phase I, Open-Label, Multicenter, First-in-Human, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Preliminary Efficacy of DXC008 in Patients With Prostate Cancer and Other Solid Tumors (Such as Ewing Sarcoma)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Hangzhou DAC Biotechnology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with prostate cancer and other solid tumors such as Ewing sarcoma.

Conditions

• Prostate Cancer
• Other Solid Tumors
• Ewing Sarcoma

Interventions

Type	Name	Description
DRUG	DXC008	Cohort A: Once every 2 weeks (Q2W) with a cycle length of 14 days. Cohort B: Once every 3 weeks (Q3W) with a cycle length of 21 days.

Timeline

• Start date: 2025-05-15
• Primary completion: 2030-04-01
• Completion: 2030-04-01
• First posted: 2025-04-13
• Last updated: 2025-09-17

Locations

3 sites across 1 country: China